H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Equillium (EQ – Research Report) today and set a price target of $15.00. The company’s shares closed last Wednesday at $3.30, close to its 52-week low of $3.18.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -28.9% and a 22.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Vallon Pharmaceuticals, and Oramed Pharmaceuticals.
Currently, the analyst consensus on Equillium is a Strong Buy with an average price target of $15.00, representing a 351.8% upside. In a report issued on March 15, Leerink Partners also initiated coverage with a Buy rating on the stock.
The company has a one-year high of $8.22 and a one-year low of $3.18. Currently, Equillium has an average volume of 58.26K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
Read More on EQ:
- Aptinyx (APTX) Gets a Buy Rating from H.C. Wainwright
- Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and iTeos Therapeutics (ITOS)
- Dollar General Updates 1 Key Risk Factor
- H.C. Wainwright Keeps Their Buy Rating on Context Therapeutics (CNTX)
- H.C. Wainwright Thinks Mogo Finance Technology’s Stock is Going to Recover